ATE549013T1 - Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren - Google Patents

Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Info

Publication number
ATE549013T1
ATE549013T1 AT10160099T AT10160099T ATE549013T1 AT E549013 T1 ATE549013 T1 AT E549013T1 AT 10160099 T AT10160099 T AT 10160099T AT 10160099 T AT10160099 T AT 10160099T AT E549013 T1 ATE549013 T1 AT E549013T1
Authority
AT
Austria
Prior art keywords
administration
reduced volume
glatiramer acetate
volume formulation
formulation
Prior art date
Application number
AT10160099T
Other languages
English (en)
Inventor
Ayelet Altman
Doris Saltkill
Dalton L Tomlinson
Tomer El-Gad
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549013(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE549013T1 publication Critical patent/ATE549013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT10160099T 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren ATE549013T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29

Publications (1)

Publication Number Publication Date
ATE549013T1 true ATE549013T1 (de) 2012-03-15

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10160099T ATE549013T1 (de) 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Country Status (19)

Country Link
US (3) US20110060279A1 (de)
EP (2) EP2275086B1 (de)
JP (1) JP2012533540A (de)
AR (1) AR077484A1 (de)
AT (1) ATE549013T1 (de)
AU (1) AU2010273234A1 (de)
BR (1) BR112012000878A2 (de)
CA (1) CA2697570C (de)
DK (1) DK2275086T3 (de)
EA (1) EA201270167A1 (de)
ES (1) ES2383347T3 (de)
HR (1) HRP20120349T1 (de)
IL (1) IL217240A0 (de)
MX (1) MX2012000687A (de)
PL (1) PL2275086T3 (de)
PT (1) PT2275086E (de)
RS (1) RS52367B (de)
WO (1) WO2011008274A2 (de)
ZA (1) ZA201200586B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
ATE549013T1 (de) 2009-07-15 2012-03-15 Teva Pharma Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
PL2627669T3 (pl) 2010-10-11 2017-02-28 Teva Pharmaceutical Industries Ltd. Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru
EP2765857A4 (de) 2011-10-10 2015-12-09 Teva Pharma Einzelnukleotidpolymorphismen zur vorhersage des klinischen ansprechens auf glatirameracetat
EP2885026B1 (de) * 2012-08-20 2023-11-08 SHL Medical AG Automatische injektionsvorrichtung
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
US8591463B1 (en) * 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
BR112015021780A2 (pt) * 2013-03-08 2017-07-18 Teva Pharmaceutical Industries Ltd dispositivo injetor reutilizável para seringa
PE20151576A1 (es) * 2013-03-08 2015-11-19 Teva Pharma Dispositivo inyector reutilizable para jeringa
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN106029019B (zh) 2014-02-26 2020-07-03 阿勒根公司 眼内植入体递送设备及其使用方法
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
JP2019533731A (ja) * 2016-11-02 2019-11-21 ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ Ｃｂｄとコパキソンの併用療法
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE55260T1 (de) * 1985-10-11 1990-08-15 Duphar Int Res Automatische spritze.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
EP1572271A1 (de) * 2002-11-25 2005-09-14 Tecpharma Licensing AG Autoinjektor mit rückstellbarer auslösesicherung
US7585843B2 (en) * 2003-10-03 2009-09-08 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2006029036A2 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
ES2572811T3 (es) * 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
CN103316402A (zh) * 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
EA201070656A1 (ru) 2007-11-28 2010-12-30 Тева Фармасьютикал Индастриз, Лтд. Способ задержки начала проявления клинически определенного рассеянного склероза
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
ATE549013T1 (de) * 2009-07-15 2012-03-15 Teva Pharma Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Also Published As

Publication number Publication date
HK1152249A1 (en) 2012-02-24
JP2012533540A (ja) 2012-12-27
IL217240A0 (en) 2012-02-29
ZA201200586B (en) 2013-10-30
WO2011008274A3 (en) 2011-09-22
EA201270167A1 (ru) 2012-08-30
US7855176B1 (en) 2010-12-21
PT2275086E (pt) 2012-05-18
EP2453907A2 (de) 2012-05-23
US9018170B2 (en) 2015-04-28
US20110066112A1 (en) 2011-03-17
WO2011008274A2 (en) 2011-01-20
US20110060279A1 (en) 2011-03-10
AR077484A1 (es) 2011-08-31
DK2275086T3 (da) 2012-07-09
MX2012000687A (es) 2012-09-07
AU2010273234A1 (en) 2012-02-23
BR112012000878A2 (pt) 2019-09-24
RS52367B (sr) 2012-12-31
ES2383347T3 (es) 2012-06-20
CA2697570A1 (en) 2010-06-22
PL2275086T3 (pl) 2012-09-28
HRP20120349T1 (hr) 2012-07-31
EP2275086A1 (de) 2011-01-19
EP2275086B1 (de) 2012-03-14
CA2697570C (en) 2011-11-01
WO2011008274A4 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
ATE549013T1 (de) Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
HUS1900031I1 (hu) Hatóanyagok légúti beadása
ES2618221T8 (es) Dispositivo de administración de prótesis vascular y método de uso
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
IL250259A0 (en) Compositions comprising ursolic acid and derivatives thereof and uses thereof
IL230786A0 (en) Heterocyclic derivative and pharmaceutical drug
EP2888265A4 (de) Bivalente inhibitoren von iap-proteinen und therapeutische verfahren damit
EP2563435A4 (de) Verabreichung von ultrareinem stickoxid
HRP20170929T1 (hr) Farmaceutski pripravci i odgovarajući postupci za isporuku
PT2780022T (pt) Preparações farmacêuticas de células epr humanas e suas utilizações
LT2603232T (lt) Stabilios linaklotido vaisto formos
IL215497B (en) Oxadiazole derivatives and pharmaceutical compositions containing them
HUE054922T2 (hu) Riszperidon és/vagy Paliperidon implantátum készítmény
DK2529756T3 (da) Risperidon- og/eller paliperidon-implantatformulering
BR112015011111A2 (pt) proteína multifuncional e formulação farmacêutica
BR112012003286A2 (pt) formulações farmacêuticas contra o mau uso dos medicamentos
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
EP2547328A4 (de) Ccr7-liganden-verabreichung und co-verabreichung in einer immuntherapie
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
EP2408912A4 (de) Foxm1-peptide und diese enthaltende impfstoffe
IL235768A0 (en) Pharmaceutical compositions and treatment of mastitis
FI20135152L (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
IL254446A0 (en) Implantable drug delivery preparations and treatment methods thereof
PL2568980T3 (pl) Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania
SI2525789T1 (sl) Farmacevtske formulacije naproksena za enkapsulacijo v mehko želatino in njihove kombinacije